Impact of SARS-CoV-2 vaccination of children ages 5–11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021–March 2022: a multi-model study

Rebecca K. Borchering, Luke C. Mullany, Emily Howerton, Matteo Chinazzi, Claire P. Smith, Michelle Qin, Nicholas G Reich, Lucie Contamin, John Levander, Jessica Kerr, Jeremy U. Espino, Harry Hochheiser, Kaitlin Lovett, Matt Kinsey, Kate Tallaksen, Shelby Wilson, Lauren Shin, Joseph C. Lemaitre, Juan Dent Hulse, Joshua Kaminsky, Elizabeth C. Lee, Alison L. Hill, Jessica T. Davis, Kunpeng Mu, Xinyue Xiong, Ana Pastore y Piontti, Alessandro Vespignani, Ajitesh Srivastava, Przemyslaw Porebski, Srini Venkatramanan, Aniruddha Adiga, Bryan Lewis, Brian Klahn, Joseph Outten, Benjamin Hurt, Jiangzhuo Chen, Henning Mortveit, Amanda Wilson, Madhav Marathe, Stefan Hoops, Parantapa Bhattacharya, Dustin Machi, Shi Chen, Rajib Paul, Daniel Janies, Jean‐Claude Thill, Marta Galanti, Teresa K. Yamana, Sen Pei, Jeffrey Shaman, Guido España, Sean Cavany, Sean M. Moore, T. Alex Perkins, Jessica M. Healy, Rachel B. Slayton, Michael A. Johansson, Matthew Biggerstaff, Katriona Shea, Shaun Truelove, Michael C. Runge, Cécile Viboud, Justin LesslerThe Lancet Regional Health - Americas 2022 · DOI

TL;DR

This study used a multi-model approach to project the impact of vaccinating 5-11 year olds against COVID-19. The findings suggest that vaccinating this age group would have provided significant direct and indirect benefits, reducing cases, hospitalizations, and deaths, and increasing resilience against new variants.

What Problem Does This Paper Address?

In late 2021, policymakers in the US were considering expanding COVID-19 vaccine eligibility to children aged 5-11. However, there was a lack of robust estimates on the potential population-level benefits of such a policy. Existing modeling studies were often limited to single models, specific geographic regions (like Australia), or focused on school-level interventions rather than national impacts. This paper aimed to fill that gap by using a coordinated modeling effort to project the impact of this vaccination expansion across various scenarios, including the emergence of new, more transmissible variants.

Methods

The study employed a "multi-model" approach, a common strategy in complex epidemiological forecasting. Nine different modeling teams contributed projections to the COVID-19 Scenario Modeling Hub. These teams generated weekly projections of cases, hospitalizations, and deaths at both national and state levels.

Four distinct scenarios were analyzed:

  1. Vaccination of children aged 5-11 years (starting November 1, 2021) vs. no vaccination.
  2. Emergence of a hypothetical variant 50% more transmissible than Delta (starting November 15, 2021) vs. no new variant.

The projections from individual teams were then "linearly pooled" to create ensemble estimates, which helps to account for the inherent uncertainty in different modeling approaches. Meta-analyses were used to estimate the overall effect of childhood vaccination on both all-age and age-specific outcomes.

Datasets

The study utilized observed COVID-19 data for model calibration up to September 11, 2021. For projecting vaccine uptake in children aged 5-11, the models used state-level uptake rates reported by the CDC for 12-17 year olds as a proxy, assuming a similar pattern would emerge for the younger group. Vaccine effectiveness estimates were based on available data for older age groups and assumed to be consistent for the hypothetical new variant.

Key Insights and Ideas

  • Childhood vaccination offers substantial population-level benefits: Even though the direct impact on the 5-11 age group might seem smaller relative to the entire population, the indirect benefits (protecting vulnerable individuals who rely on herd immunity) are significant.
  • Resilience against variants is a key benefit: The models showed that vaccinating younger children would be particularly important in mitigating the impact of more transmissible variants, enhancing the overall resilience of the population.
  • Heterogeneity matters: While national trends were projected, the study also acknowledged state-level variations in impact, suggesting that local factors like vaccination coverage and population demographics play a crucial role.
  • The "what-if" scenario is powerful: By modeling hypothetical variants, the study provided a stress test that highlighted the potential value of vaccination in more challenging epidemiological circumstances.

Key Results

  • Without a new variant: Vaccinating children aged 5-11 was projected to reduce all-age cumulative cases by 7.2% (mean incidence ratio [IR] 0.928), hospitalizations by 8.7% (mean IR 0.913), and deaths by 9.2% (mean IR 0.908) between November 2021 and March 2022.
  • With a more transmissible variant: The benefits increased significantly. Cases were projected to reduce by 10.1% (mean IR 0.899), hospitalizations by 11.8% (mean IR 0.882), and deaths by 12.3% (mean IR 0.877).
  • Younger age group benefits: Projections indicated that relative reductions in reported cases were larger for the younger age group (5-11 years) compared to the overall population, underscoring the direct protective effect.
  • State-level variation: Median overall population-level reduction in reported cases was 5.8% in scenarios without a new variant, and 11.0% with a more transmissible variant, with ranges showing considerable state-level differences.

Limitations and Future Work

  • Assumed vaccine effectiveness: The study assumed vaccine effectiveness in children 5-11 years old would match that of older age groups. Later data on Omicron showed lower effectiveness and waning immunity, which could alter these projections.
  • Optimistic vaccine uptake: The models assumed higher vaccine uptake in children than was ultimately realized, which would lead to lower actual benefits.
  • Hypothetical variant: The modeled variant was a simplification; the real-world Omicron variant had characteristics (like immune escape) not fully captured, making direct comparison challenging.
  • Short projection period: The study focused on a few months (November 2021-March 2022). Longer-term benefits, dependent on immunity duration and viral evolution, were not fully assessed.
  • Limited outcomes: The study focused on cases, hospitalizations, and deaths, not including broader societal impacts like missed school or work days, or economic costs, which would likely increase the perceived benefits of vaccination.

Future work could involve refining models to account for more complex variant characteristics, real-world vaccine uptake, and longer-term projections. The authors also highlight the need for better methods to evaluate scenario projection performance retrospectively, especially when real-world events diverge from hypothetical scenarios.

Summary updated

Abstract

Various (see acknowledgments).
BibTeX
@inproceedings{borchering2022impact,
  author = {Rebecca K. Borchering and Luke C. Mullany and Emily Howerton and Matteo Chinazzi and Claire P. Smith and Michelle Qin and Nicholas G Reich and Lucie Contamin and John Levander and Jessica Kerr and Jeremy U. Espino and Harry Hochheiser and Kaitlin Lovett and Matt Kinsey and Kate Tallaksen and Shelby Wilson and Lauren Shin and Joseph C. Lemaitre and Juan Dent Hulse and Joshua Kaminsky and Elizabeth C. Lee and Alison L. Hill and Jessica T. Davis and Kunpeng Mu and Xinyue Xiong and Ana Pastore y Piontti and Alessandro Vespignani and Ajitesh Srivastava and Przemyslaw Porebski and Srini Venkatramanan and Aniruddha Adiga and Bryan Lewis and Brian Klahn and Joseph Outten and Benjamin Hurt and Jiangzhuo Chen and Henning Mortveit and Amanda Wilson and Madhav Marathe and Stefan Hoops and Parantapa Bhattacharya and Dustin Machi and Shi Chen and Rajib Paul and Daniel Janies and Jean‐Claude Thill and Marta Galanti and Teresa K. Yamana and Sen Pei and Jeffrey Shaman and Guido España and Sean Cavany and Sean M. Moore and T. Alex Perkins and Jessica M. Healy and Rachel B. Slayton and Michael A. Johansson and Matthew Biggerstaff and Katriona Shea and Shaun Truelove and Michael C. Runge and Cécile Viboud and Justin Lessler},
  title = {{Impact of SARS-CoV-2 vaccination of children ages 5–11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021–March 2022: a multi-model study}},
  booktitle = {The Lancet Regional Health - Americas},
  year = {2022},
  doi = {10.1016/j.lana.2022.100398},
}
Figure